Optimizing Oncology Denial Management for Complex Cancer Care

Effective oncology denial management is critical for maintaining revenue integrity and ensuring continuity of care for patients undergoing complex cancer treatments.

The intricate nature of oncology prior authorizations, encompassing high-cost biologics, frequent regimen changes, and advanced imaging, inevitably leads to a significant volume of denials. Manually navigating these appeals drains resources and delays patient access to vital therapies. Klivira provides a specialized approach to automate and streamline this complex workflow.

The Unique Challenges of Oncology Denials

Oncology presents a unique landscape for denial management due to its high-cost therapies, rapid treatment advancements, and the critical urgency of care. Denials often stem from the complexity of regimens, specific documentation requirements for novel agents, and the dynamic nature of cancer treatment protocols.

Common Triggers for Oncology PA Denials

Off-label use without NCCN Compendium support for chemotherapy regimens and biologics.
Step therapy requirements for biologics and oral oncolytics with biosimilar or class alternatives.
Documentation gaps regarding pathology reports, prior-line treatment response, or molecular marker results.
Site-of-service mismatches for infusion therapy or radiation oncology procedures.
NCD/LCD non-coverage for advanced imaging (PET/CT) or specific genetic testing panels.

Automating Denial Ingestion and Root Cause Analysis

Klivira centralizes denial intake from all channels, including X12 835 for billed services and X12 277 for pre-service PA denials. Our platform normalizes X12 CARC/RARC codes and payer-specific variations into a uniform reason set, enabling precise categorization and root-cause identification for oncology-specific denials.

Streamlining Oncology Appeal Workflows

Auto-routing denials to appropriate pathways: claim correction, appeal, or peer-to-peer review, based on normalized reason and payer policy.
Automated appeal-packet assembly, pulling additional clinical documentation from the EMR via FHIR, including updated lab results or new physician notes.
Timely-filing window enforcement and proactive deadline surfacing to prevent missed appeal opportunities for time-sensitive oncology cases.
Integration with NCCN Clinical Practice Guidelines to strengthen medical necessity arguments for complex regimens.

Addressing Specialty-Specific Operational Constraints

Oncology's start-of-treatment urgency and frequent regimen changes demand an agile denial management system. Klivira's platform supports regimen-level PA tracking and concurrent PA event management, ensuring that appeals for combined therapies or subsequent lines of treatment are handled efficiently, minimizing delays in patient care.

Enhancing Peer-to-Peer Review and Feedback Loops

For high-acuity clinical-necessity denials common in oncology, Klivira facilitates peer-to-peer scheduling integration, routing requests to ordering oncologists and tracking status. Furthermore, denial pattern reporting feeds back into upstream PA submission processes, improving accuracy and reducing future denials related to specific oncology drugs or procedures.

Frequently asked questions

How does Klivira handle denials for oncology drugs split between medical and pharmacy benefits?

Klivira's system is designed to recognize the benefit split. Denials for medical-benefit drugs (IV chemotherapy, biologics) are ingested from X12 835/277 or payer portals, while pharmacy-benefit oral oncolytics denials are routed via PBM channels or ePA partners, ensuring the correct appeal pathway is initiated.

Can Klivira help appeal denials related to NCCN guideline discrepancies?

Yes, Klivira's NCCN-compendium-aware policy logic is integrated into the appeal process. For denials citing lack of medical necessity, the system helps assemble appeal packets that reference specific NCCN Compendium categories (e.g., Category 1, 2A) and relevant clinical evidence from the EMR via FHIR, strengthening the appeal.

How does Klivira prevent timely-filing breaches for oncology appeals?

Klivira enforces per-payer timely-filing windows for all oncology appeals. The system proactively surfaces deadlines and provides automated alerts and escalations if an appeal's status is not updated within configurable thresholds, significantly reducing the risk of missed appeal opportunities.

What kind of documentation does Klivira automatically pull for oncology appeals?

For oncology appeals, Klivira leverages FHIR to pull relevant clinical documentation from the EMR. This includes pathology reports, tumor staging (AJCC TNM), molecular marker results (e.g., EGFR, PD-L1), prior-line treatment history, performance status (ECOG/Karnofsky), and updated physician notes or lab results that support the medical necessity of the requested treatment.

Does Klivira address denials for complex radiation oncology procedures?

Yes, denials for radiation oncology procedures like IMRT, IGRT, SBRT, or proton-beam therapy are often related to documentation around treatment plans, dose, and fractionation. Klivira's system can help assemble appeal packets with the required clinical rationale and comparative dosimetry where applicable, drawing from EMR data.